$1.86
6.53% today
Nasdaq, Apr 03, 06:45 pm CET
ISIN
US09075P1057
Symbol
BTAI
Sector
Industry

BioXcel Therapeutics, Inc. Stock price

$1.99
-1.76 46.93% 1M
-6.65 76.96% 6M
-3.99 66.74% YTD
-40.25 95.29% 1Y
-325.85 99.39% 3Y
-298.01 99.34% 5Y
-174.49 98.87% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.07 3.65%
ISIN
US09075P1057
Symbol
BTAI
Sector
Industry

Key metrics

Market capitalization $10.92m
Enterprise Value $84.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 37.01
P/S ratio (TTM) P/S ratio 4.81
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 64.20%
Revenue (TTM) Revenue $2.27m
EBIT (operating result TTM) EBIT $-63.47m
Free Cash Flow (TTM) Free Cash Flow $-72.03m
Cash position $29.85m
EPS (TTM) EPS $-25.91
P/E forward negative
P/S forward 2.25
EV/Sales forward 17.33
Short interest 7.69%
Show more

Is BioXcel Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

BioXcel Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a BioXcel Therapeutics, Inc. forecast:

3x Buy
75%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a BioXcel Therapeutics, Inc. forecast:

Buy
75%
Sell
25%

Financial data from BioXcel Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2.27 2.27
64% 64%
100%
- Direct Costs 2.45 2.45
48% 48%
108%
-0.19 -0.19
30% 30%
-8%
- Selling and Administrative Expenses 34 34
59% 59%
1,489%
- Research and Development Expense 29 29
65% 65%
1,286%
-63 -63
62% 62%
-2,783%
- Depreciation and Amortization 0.31 0.31
21% 21%
14%
EBIT (Operating Income) EBIT -63 -63
62% 62%
-2,796%
Net Profit -60 -60
67% 67%
-2,626%

In millions USD.

Don't miss a Thing! We will send you all news about BioXcel Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioXcel Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI ® in the at-home setting Strengthened cash position to advance BX...
Neutral
GlobeNewsWire
23 days ago
Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI ®  in the home setting
Neutral
GlobeNewsWire
27 days ago
Data to support potential sNDA submission for label expansion of IGALMI ® in the home setting
More BioXcel Therapeutics, Inc. News

Company Profile

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Head office United States
CEO Vimal Mehta
Employees 37
Founded 2017
Website www.bioxceltherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today